Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5895840 | 0.88 | SPR (0.35) | CRBNDDB1SPRRIPK1 | |
| SCHEMBL18321890 | 0.86 | SPR (0.36) | CRBNDDB1SPRRIPK1 | |
| SCHEMBL18711765 | 0.82 | USP2 (0.41) | SPR | |
| SCHEMBL1847022 | 0.81 | CRBN (0.34) | CRBNDDB1RIPK1 | |
| SCHEMBL16914279 | 0.78 | CRBN (0.33) | CRBNDDB1RIPK1 | |
| SCHEMBL16914308 | 0.78 | CRBN (0.33) | CRBNDDB1RIPK1 | |
| SCHEMBL18701962 | 0.77 | CYP3A4 (0.39) | CRBNSPRRIPK1 | |
| SCHEMBL8812011 | 0.75 | DDB1 (0.34) | CRBNDDB1RIPK1 | |
| SCHEMBL30883491 | 0.75 | CRBN (0.31) | CRBNRBP4 | |
| SCHEMBL2159192 | 0.73 | CRBN (0.33) | CRBNDDB1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| US-12012393-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-3724178-B1 | 1-(PIPERIDINOCARBONYLMETHYL)-2-OXOPIPERAZINE DERIVATIVES FOR TREATING CANCER | Inthera Bioscience AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| EP-4320129-A1 | GPR119 AGONISTS | Kallyope, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2022-07-07 | — | — | US | disclosed |
| CN-108289886-B | Ion channel inhibiting compounds, pharmaceutical formulations and uses | 安华赛公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20200308139-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2020-10-01 | — | — | US | disclosed |
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-08-06 | — | — | US | disclosed |
| US-10710975-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2020-07-14 | — | — | US | disclosed |
| EP-3645533-A1 | TDO2 AND IDO1 INHIBITORS | Genentech, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019005559-A1 | TDO2 AND IDO1 INHIBITORS | GENENTECH, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | AFASCI, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| CN-108289886-A | Ion channel inhibiting compound, pharmaceutical preparation and purposes | 安华赛公司 | 2018-07-17 | — | — | CN | disclosed |
| EP-3310779-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| WO-2018071317-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
| WO-2016203404-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| EP-3094628-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2016-11-23 | — | — | EP | disclosed |
| WO-2015107495-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2015-07-23 | — | — | WO | disclosed |
| US-7091211-B2 | Cyclopentyl modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | CRBN 4270/4885DDB1 4086/4885SPR 3878/4885 |
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | CRBN 1101/4885DDB1 3343/4885SPR 2714/4885 |
| US-10710975-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | CRBN 4270/4885DDB1 4086/4885SPR 3878/4885 |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | CRBN 298/4885DDB1 1142/4885SPR 1350/4885 |
| US-20200308139-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | CRBN 4270/4885DDB1 4086/4885SPR 3878/4885 |
| US-12012393-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | CRBN 4270/4885DDB1 4086/4885SPR 3878/4885 |
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR5, CXCR1, ACKR3 | CRBN 4573/4885DDB1 1167/4885SPR 450/4885 |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | CACNA1I, CACNA1G, CACNA1H | CRBN 3976/4885DDB1 4782/4885SPR 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.